AN2 Therapeutics
ANTX
AN2 Therapeutics (ANTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.21
- EPS estimate
- −$0.34
- EPS surprise
- +37.31%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.34 | −$0.21 | +37.31% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.27 | −$0.35 | −32.08% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.27 | −$0.25 | +7.41% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.45 | −$0.43 | +4.44% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.61 | −$0.48 | +20.79% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.62 | −$0.56 | +9.68% | $0.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$0.74 | −$0.57 | +22.55% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.65 | −$0.65 | −0.39% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.85 | −$0.81 | +4.99% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.66 | −$0.79 | −20.15% | $0.00 | SEC |
| Q4 2022 | Mar 29, 2023 | −$0.63 | −$0.61 | +3.56% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.59 | −$0.59 | +0.42% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$1.54 | −$0.53 | +65.53% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.93 | −$2.98 | −220.43% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did AN2 Therapeutics (ANTX) last report earnings?
AN2 Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did ANTX beat earnings estimates?
Yes. AN2 Therapeutics reported EPS of −$0.21 for Q2 2025 against a −$0.34 estimate — a 37.31% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.